Biopharma | December 04, 2025
Aelis Farma gets EMA nod for phase 2B trial of AEF0217 in down syndrome
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
Here's a development that aims to keep your blood pressure in check. Literally!
The company is excluding data from the affected sites to maintain the study's integrity
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
Angelini Ventures has already invested €125 million in 22 startups
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
Subscribe To Our Newsletter & Stay Updated
